SCHEMBL2709792

SCHEMBL2709792

COc1ccccc1-c1cccc(OC)c1P(C1CCCCC1)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.42
TP53 P04637 1/20 0.42
HTR7 P34969 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
S1PR1 P21453 1/20 0.39
LMNA P02545 1/20 0.38
HIF1A Q16665 1/20 0.38
PTPRC P08575 1/20 0.38
PTPN1 P18031 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21331777 0.95 SMN1; SMN2 (0.43) HPGDSMN1; SMN2RAB9ANPC1TSHR
SCHEMBL1102294 0.87 ABCB1 (0.43) HPGDSMN1; SMN2LMNAPOLBABCB1
SCHEMBL16694832 0.85 ABCB1 (0.41) HPGDSMN1; SMN2TSHRTP53CHRM2
SCHEMBL21331833 0.83 HTR1A (0.41) HPGDSMN1; SMN2RAB9ANPC1TSHR
SCHEMBL30821692 0.83 SMN1; SMN2 (0.43) HPGDSMN1; SMN2RAB9ANPC1TSHR
SCHEMBL1291696 0.83 SMN1; SMN2 (0.43) HPGDSMN1; SMN2RAB9ANPC1TSHR
SCHEMBL11954834 0.83 ABCB1 (0.40) HPGDSMN1; SMN2LMNAABCB1
SCHEMBL16626228 0.81 ABCB1 (0.39) HPGDSMN1; SMN2LMNAPOLBABCB1
SCHEMBL28515615 0.81 HPGD (0.40) HPGDSMN1; SMN2RAB9ANPC1TSHR
SCHEMBL30012881 0.81 HTR7 (0.40) HPGDSMN1; SMN2RAB9ANPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020052774-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-03-19 WO disclosed
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
EP-2445987-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS Cyalume Technologies, Inc (US) 2012-05-02 EP disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
WO-2010151654-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECHNOLOGIES, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 HPGD 381/4885SMN1; SMN2 4856/4885RAB9A 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.